KURA ONCOLOGY, INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax
KURA ONCOLOGY, INC. (KURA) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax of $210.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax · last filed 2025-05-01
- KURA ONCOLOGY, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2025-03-31 was $210.00K, a 53.85% decline year-over-year.
- KURA ONCOLOGY, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for the quarter ending 2024-03-31 was $455.00K.
- KURA ONCOLOGY, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2024 was -$2.04M.
- KURA ONCOLOGY, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2023 was -$6.76M, a 208.30% decline from fiscal 2022.
- KURA ONCOLOGY, INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment, tax for fiscal 2022 was $6.24M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax 12 month |
|---|---|---|
| 2025-03-31 | $210.00K 10-Q · filed 2025-05-01 | |
| 2024-12-31 | -$2.04M 10-K · filed 2025-02-28 | |
| 2024-03-31 | $455.00K 10-Q · filed 2025-05-01 | |
| 2023-12-31 | -$6.76M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $6.24M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |